Wealth Awesome
TSX open
Loading markets…
Interactive Brokers: IBKR clients beat the S&P 500 in 2025 — 19.20% average client return vs 17.9% for the index, net of commissions and charges.
Stocks/TSX/BHC

Bausch Health Companies Inc (BHC : TSX)

$12.05CAD+0.14 (1.18%)Close of 2026-11-16

Common Stock

Follow BHC

BHC

Bausch Health Companies Inc

Source:WealthAwesomeWealthAwesome
↑ $3.63 (43.11%)
30 day period
$8.36$10.38$12.41Oct 5Oct 27Nov 16

Performance

1 Day

+1.18%

1 Week

+1.43%

1 Month

+35.09%

YTD

+21.47%

The Saturday TSX Wrap · free, every saturday morning. The week on the TSX, in five minutes.

Key Statistics

Market Cap

$4.46B

52W High

$12.65

52W Low

$6.10

P/E Ratio

-

50 Day MA

$9.11

200 Day MA

$7.99

Beta

0.28

Dividend Yield

-

WA Score

How BHC stacks up against 944 Canadian stocks

out of 99

  • Value9

    Not profitable over the last 12 months.

  • Quality
  • Momentum84

    21.5% this year, above its 200-day average, 91% of the way up its 52-week range.

  • Analysts
  • Insiders

Each factor is a percentile against Canadian common stocks worth $50M or more on the TSX and TSX Venture (90 = better than 90% of them). Built from exchange prices, company financials, analyst targets and SEDI insider filings. A data summary, not advice. How it works · Top-scoring stocks

Performance history

BHC returns since 2016

Bausch Health Companies Inc has returned −6.7% a year over the last 10 years, with 5 up years out of 9 full calendar years. Its deepest fall was −96.2% (Jan 2016 to Jul 2022).

1 year / yr

+39.8%

3 years / yr

+10.0%

5 years / yr

−18.4%

10 years / yr

−6.7%

Calendar-year returns

  • 2016*−85.8%
  • 2017+34.6%
  • 2018−3.6%
  • 2019+53.9%
  • 2020−32.1%
  • 2021+32.3%
  • 2022−75.7%
  • 2023+25.1%
  • 2024+9.3%
  • 2025−18.0%
  • 2026*+26.4%

* Partial year (first year of data, or year to date).

$10,000 invested in BHC

  • 1 year ago$13,979
  • 5 years ago$3,611
  • 10 years ago$5,015
Best year
2019: +53.9%
Worst year
2022: −75.7%
All-time high in our data
$144 on Jan 6, 2016 · now −91.6%

Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jan 2016 to Nov 2026. Past returns do not predict future ones.

Earnings

BHC earnings history

Bausch Health Companies Inc beat the EPS estimate in 3 of its last 4 reported quarters.

Next report

Feb 17, 2027 · after close

EPS estimate $1.32

0.00000.88501.7700 24-1225-0325-0625-0925-1226-0326-0626-09 Estimate Actual (≥0) Actual (<0) Wealth Awesome
Quarter endingReportedEPSEstimateSurprise
Sep 30, 2026Oct 28, 2026$1.77$1.24+42.7%
Jun 30, 2026Jul 29, 2026$1.26$1.01+24.8%
Mar 31, 2026Apr 29, 2026$0.78$0.69+13.0%
Dec 31, 2025Feb 18, 2026$1.10$1.21−9.1%
Sep 30, 2025Oct 29, 2025$1.16$1.06+9.4%
Jun 30, 2025Jul 30, 2025$0.91$0.94−3.2%
Mar 31, 2025Apr 30, 2025$0.61$0.85−28.2%
Dec 31, 2024Feb 20, 2025$1.16$1.13+2.9%

EPS as reported vs consensus estimate. TSX earnings calendar →

Awesome Portfolio™

Looking past BHC? Our 10 best Canadian stocks, in one list.

14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.

See the portfolio →

Bausch Health Companies Inc insider transactions

Open-market and private equity trades (last 12 months volume). Derivatives and opening balances excluded.

Recent transactions

DateSideNameSharesPrice
Nov 26, 08Sell
Melnyk, Eugene
Individual · CA$815
100CA$8.15
Nov 26, 08Sell
Melnyk, Eugene
Individual · CA$809
100CA$8.09
Nov 26, 08Sell
Melnyk, Eugene
Individual · CA$145,070
17,800CA$8.15
Nov 26, 08Sell
Melnyk, Eugene
Individual · CA$5,719
700CA$8.17
Nov 26, 08Sell
Melnyk, Eugene
Individual · CA$10,634
1,300CA$8.18
Nov 26, 08Sell
Melnyk, Eugene
Individual · CA$1,638
200CA$8.19
Nov 26, 08Sell
Melnyk, Eugene
Individual · CA$38,540
4,700CA$8.20
Nov 26, 08Sell
Melnyk, Eugene
Individual · CA$203,750
25,000CA$8.15
Nov 26, 08Sell
Melnyk, Eugene
Individual · CA$2,463
300CA$8.21
Nov 26, 08Sell
Melnyk, Eugene
Individual · CA$196,697
23,900CA$8.23

Full BHC insider trading page →

Technical Indicators

Price vs 50-Day SMA

↑Above 50 SMA

Price vs 200-Day SMA

↑Above 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
11/16/2026$12.02$12.26$11.97$12.05$12.05901,674
11/13/2026$11.76$11.99$11.67$11.91$11.91484,273
11/12/2026$11.96$12.02$11.76$11.76$11.76329,236
11/11/2026$11.88$12.04$11.56$11.91$11.91523,698
11/10/2026$11.82$11.85$11.57$11.78$11.78662,127
11/9/2026$11.62$12.10$11.59$11.88$11.88620,695
11/6/2026$11.15$11.58$11.15$11.56$11.56850,864
11/5/2026$11.60$11.71$11.16$11.19$11.19898,272
11/4/2026$11.56$11.81$11.50$11.67$11.67522,306
11/3/2026$11.09$11.45$11.07$11.41$11.41640,076

Analyst Price Targets

Based on analyst covering BHC · as of Sep 17, 2026

📉

Wall Street analysts forecast BHC stock price to fall 41.8% over the next 12 months.

Consensus

Bearish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$7.01

-41.8% Upside

Current Price

C$12.05

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on BHC's historical volatility

HistoricalForecast68%95%
C$5.03C$12.27C$19.52C$26.77C$34.01C$41.26TodayJul 9Sep 14Nov 16Dec 29Feb 11Mar 26

30-Day Vol

85.6%

Annualized

90-Day Vol

77.6%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

C$14.41

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$12.79C$9.52 – C$17.18
60 trading daysC$13.57C$8.94 – C$20.61
90 trading daysC$14.41C$8.64 – C$24.02

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Bausch Health Companies Inc

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Financials

Revenue (TTM)
$11.11B
EBITDA
$4.17B
Profit Margin
-7.57%
ROE (TTM)
-11040.00%
EPS (Diluted)
-3.14
Book Value
-4.98

Classification

Sector
Health Care
Industry
Pharmaceuticals
Group
Pharmaceuticals, Biotechnology & Life Sciences

Free newsletter

The Saturday TSX Wrap

Saturday morning

The week on the TSX, in five minutes

  • The biggest gainers and losers, and why they moved
  • Sector and momentum moves at a glance
  • The Canadian market stories you missed

Free. One email a week. Unsubscribe any time.

Common Questions About BHC

Market movers

Recent TSX movers

Top 1-day gainers — updated from our Canadian movers feed.

All movers →
TickerNamePrice1D
HWOHigh Arctic Energy Services Inc.$1.74+29.85%
AAVAdvantage Oil & Gas Ltd.$13.45+23.74%
LUCLucara Diamond Corp$0.13+13.64%
TTelus Corp$13.70+12.85%
FRXFennec Pharmaceuticals Inc$18.35+10.81%
KELKelt Exploration Ltd.$12.72+10.70%
NVONovo Resources Corp$0.07+8.33%
ELOEloro Resources Ltd.$1.23+7.89%

Free with a Wealth Awesome account

Keep analysing BHC, free

  • Every WA Score, ranking and table
  • Insider track records and SEDI filings
  • Earnings history and analyst targets for every stock

Email only, no password, no card. Already a member? Use the same button to sign in.